Oncology Central

Induction chemotherapy in head and neck cancer: are we too ambitious?


Induction chemotherapy is not to be considered standard of care in locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN) [1]. The coffin of induction chemotherapy is even about to be nailed [2]. The causes of the apparently imminent demise are diverse. SCCHN is a heterogeneous disease with prognosis depending on tumor site, T and N stage, etiology of the disease (human papilloma virus, smoking or drinking). Consequently, in order to include sufficient patients, most induction chemotherapy trials enrolled patients with a wide variation in risk of local and/or distant relapse.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.